03 Jun Prostate cancer – intermittent hormone therapy inferior to continuous for SOME men.
These are real issues for men with prostate cancer and this study offers some basic guidance to men and their families who seek get as much quality as they can into their lives.
This eye catching headline is a misleading and a confusing one yet again for men that are struggling to find a compromise between over treatment and under treatment.
Dr Maha Hussain of the University of Michigan CCC will present the findings of the study today at ASCO 2012 in Chicago.
He will report the findings of the study that show that in jargon free language:-
For patients with minimal disease, continuous androgen deprivation (AD) was superior to intermittent AD.
For patients with extensive disease, overall survival was comparable between intermittent and continuous AD.
For ALL patients their were benefits in quality of life issues.
Follow the link below to read about the study and its findings.